Potent antitumor activity of the Ad5/11 chimeric oncolytic 
adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis

Wei,Xubin; Liu,Li; Wang,Gang; Li,Wei; Xu,Ke; Qi,Hongyan; Liu,Hong; Shen,Jing; Li,Zhongjie; Shao,Jimin

doi:10.3892/or.2014.3563

Potent antitumor activity of the Ad5/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis

Authors:
- Xubin Wei
- Li Liu
- Gang Wang
- Wei Li
- Ke Xu
- Hongyan Qi
- Hong Liu
- Jing Shen
- Zhongjie Li
- Jimin Shao
View Affiliations

Affiliations: Department of Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China, School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, Zhejiang 310018, P.R. China
Published online on: October 22, 2014 https://doi.org/10.3892/or.2014.3563
Pages: 111-118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Ad5/11 chimeric oncolytic adenovirus represents a promising new platform for anticancer therapy. Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic progenitor cells and is the most common malignant myeloid disorder in adults. Myeloid and other hematopoietic cell lineages are involved in the process of clonal proliferation and differentiation. In the present study, we aimed to ascertain whether chimeric oncolytic adenovirus-mediated transfer of the human interleukin-24 (IL-24) gene induces enhanced antitumor potency. Our results showed that the Ad5/11 chimeric oncolytic adenovirus carrying hIL-24 (AdCN205‑11-IL-24) produced high levels of hIL-24 in AML cancer cells, as compared with the Ad5 oncolytic adenovirus expressing hIL-24 (AdCN205-IL-24). AdCN205-11-IL-24 specifically induced a cytotoxic effect on AML cancer cells, but had little or no effect on a normal cell line. AdCN205-11-IL-24 induced higher antitumor activity in AML cancer cells by inducing apoptosis in vitro. This study suggests that transfer of IL-24 by an Ad5/11 chimeric oncolytic adenovirus may be a potent antitumor approach for AML cancer therapy.

View Figures

View References

1	Estey E and Dohner H: Acute myeloid leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
2	Frohling S, Scholl C, Gilliland DG and Levine RL: Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 23:6285–6295. 2005. View Article : Google Scholar : PubMed/NCBI
3	Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood. 107:3481–3485. 2006. View Article : Google Scholar : PubMed/NCBI
4	Downing JR: The core-binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev. 13:48–54. 2003. View Article : Google Scholar : PubMed/NCBI
5	Scholl C, Gilliland DG and Frohling S: Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol. 35:336–345. 2008. View Article : Google Scholar : PubMed/NCBI
6	Kornblau SM, Womble M, Qiu YH, et al: Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 108:2358–2365. 2006. View Article : Google Scholar : PubMed/NCBI
7	Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE and McCubrey JA: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18:189–218. 2004. View Article : Google Scholar : PubMed/NCBI
8	Sangro B and Prieto J: Gene therapy for liver cancer: clinical experience and future prospects. Curr Opin Mol Ther. 12:561–569. 2010.PubMed/NCBI
9	Denefle PP: Introduction to gene therapy: a clinical aftermath. Methods Mol Biol. 737:27–44. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE and Gerson SL: Cancer gene therapy: scientific basis. Annu Rev Med. 53:437–452. 2002. View Article : Google Scholar : PubMed/NCBI
11	Pfeifer A and Verma IM: Gene therapy: promises and problems. Annu Rev Genomics Hum Genet. 2:177–211. 2001. View Article : Google Scholar : PubMed/NCBI
12	Qian C, Sangro B and Prieto J: New strategies to enhance gene therapy efficiency. Gastroenterology. 123:639–642. 2002. View Article : Google Scholar : PubMed/NCBI
13	Wong HH, Lemoine NR and Wang Y: Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses. 2:78–106. 2010. View Article : Google Scholar : PubMed/NCBI
14	Qian C, Liu XY and Prieto J: Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res. 16:182–188. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kirn D, Martuza RL and Zwiebel J: Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med. 7:781–787. 2001. View Article : Google Scholar : PubMed/NCBI
16	Singer O and Verma IM: Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr Gene Ther. 8:483–488. 2008. View Article : Google Scholar : PubMed/NCBI
17	Berk AJ: Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene. 24:7673–7685. 2005. View Article : Google Scholar : PubMed/NCBI
18	Zhang W, Cai R, Luo J, et al: The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biol Ther. 6:1726–1732. 2007. View Article : Google Scholar
19	Sherr CJ and McCormick F: The RB and p53 pathways in cancer. Cancer Cell. 2:103–112. 2002. View Article : Google Scholar : PubMed/NCBI
20	Cui Q, Jiang W, Wang Y, et al: Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma. Hepatology. 47:105–112. 2008. View Article : Google Scholar
21	Papadakis ED, Nicklin SA, Baker AH and White SJ: Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther. 4:89–113. 2004. View Article : Google Scholar : PubMed/NCBI
22	Luo J, Xia Q, Zhang R, et al: Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res. 14:2450–2457. 2008. View Article : Google Scholar : PubMed/NCBI
23	Segerman A, Mei YF and Wadell G: Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. J Virol. 74:1457–1467. 2000. View Article : Google Scholar : PubMed/NCBI
24	Lyons M, Onion D, Green NK, et al: Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 14:118–128. 2006. View Article : Google Scholar : PubMed/NCBI
25	Yu L, Shimozato O, Li Q, et al: Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res. 27:2311–2316. 2007.PubMed/NCBI
26	Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y and Fisher PB: Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 22:929–979. 2004. View Article : Google Scholar : PubMed/NCBI
27	Lebedeva IV, Emdad L, Su ZZ, et al: mda-7/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol. 31:985–1007. 2007.PubMed/NCBI
28	Fisher PB: Is mda-7/IL-24 a ‘magic bullet’ for cancer? Cancer Res. 65:10128–10138. 2005. View Article : Google Scholar : PubMed/NCBI
29	Sauane M, Gopalkrishnan RV, Sarkar D, et al: MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev. 14:35–51. 2003. View Article : Google Scholar
30	Qian W, Liu J, Tong Y, et al: Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia. 22:361–369. 2008. View Article : Google Scholar
31	Zhao L, Dong A, Gu J, et al: The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther. 13:1011–1022. 2006. View Article : Google Scholar : PubMed/NCBI
32	Aghi M and Martuza RL: Oncolytic viral therapies - the clinical experience. Oncogene. 24:7802–7816. 2005. View Article : Google Scholar : PubMed/NCBI
33	Mathis JM, Stoff-Khalili MA and Curiel DT: Oncolytic adeno-viruses - selective retargeting to tumor cells. Oncogene. 24:7775–7791. 2005. View Article : Google Scholar : PubMed/NCBI
34	Wong HH, Jiang G, Gangeswaran R, et al: Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol Ther. 20:306–316. 2012. View Article : Google Scholar :
35	Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G and Arnberg N: Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 77:9183–9191. 2003. View Article : Google Scholar : PubMed/NCBI